Omalizumab Re-Treatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA Trial.

Background: Omalizumab shows greater clinical benefit with 300 mg dose than with the 150 mg dose.

Objective: To determine outcomes postwithdrawal, relapse, and re-treatment in omalizumab responders, and from stepping up to 300 mg after insufficient symptom control with 150 mg.

Methods: This was a prospective, randomized (3:4), open-label, noncomparator study (clinicaltrials.